NasdaqGS:ISEE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has IVERIC bio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ISEE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ISEE's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

14.1%

ISEE

3.6%

US Biotechs

2.8%

US Market


1 Year Return

95.9%

ISEE

23.4%

US Biotechs

20.7%

US Market

Return vs Industry: ISEE exceeded the US Biotechs industry which returned 23.4% over the past year.

Return vs Market: ISEE exceeded the US Market which returned 20.7% over the past year.


Shareholder returns

ISEEIndustryMarket
7 Day14.1%3.6%2.8%
30 Day11.1%12.6%12.3%
90 Day51.8%9.7%6.4%
1 Year95.9%95.9%25.5%23.4%23.4%20.7%
3 Year106.9%106.9%23.7%17.3%47.2%37.4%
5 Year-90.0%-90.0%14.0%6.1%94.1%72.7%

Long-Term Price Volatility Vs. Market

How volatile is IVERIC bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is IVERIC bio undervalued compared to its fair value and its price relative to the market?

2.76x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ISEE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ISEE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ISEE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ISEE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ISEE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ISEE is good value based on its PB Ratio (2.8x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is IVERIC bio forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-0.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ISEE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ISEE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ISEE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ISEE's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ISEE's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ISEE is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has IVERIC bio performed over the past 5 years?

29.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ISEE is currently unprofitable.

Growing Profit Margin: ISEE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ISEE is unprofitable, but has reduced losses over the past 5 years at a rate of 29.5% per year.

Accelerating Growth: Unable to compare ISEE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ISEE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: ISEE has a negative Return on Equity (-35.69%), as it is currently unprofitable.


Next Steps

Financial Health

How is IVERIC bio's financial position?


Financial Position Analysis

Short Term Liabilities: ISEE's short term assets ($234.4M) exceed its short term liabilities ($19.9M).

Long Term Liabilities: ISEE's short term assets ($234.4M) exceed its long term liabilities ($76.0K).


Debt to Equity History and Analysis

Debt Level: ISEE is debt free.

Reducing Debt: ISEE has no debt compared to 5 years ago when its debt to equity ratio was 151.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ISEE has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ISEE has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 13.2% each year


Next Steps

Dividend

What is IVERIC bio current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ISEE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ISEE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ISEE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ISEE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ISEE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Glenn Sblendorio (64 yo)

3.33yrs

Tenure

US$2,462,148

Compensation

Mr. Glenn P. Sblendorio, M.B.A., has been the President of IVERIC bio, Inc. (formerly known as Ophthotech Corporation) since February 1, 2017 and has been its Chief Executive Officer since July 1, 2017. Mr...


CEO Compensation Analysis

Compensation vs Market: Glenn's total compensation ($USD2.46M) is above average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Glenn's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
David Guyer
Executive Chairman13.83yrsUS$1.81m0.060%
$ 340.0k
Glenn Sblendorio
CEO, President & Director3.33yrsUS$2.46m0.25%
$ 1.4m
David Carroll
Senior VP3.58yrsUS$1.44m0.038%
$ 212.3k
Keith Westby
Senior VP & COO3.83yrsUS$1.43m0.046%
$ 258.2k
Samir Patel
Co-Founder and Consultant13.83yrsno datano data
Abraham Scaria
Chief Scientific Officer1.08yrsno datano data
Kathy Galante
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Todd Anderman
VP, General Counsel & Corporate Secretary2.83yrsno datano data
Amy Sheehan
Senior VP & Chief Human Resources Officer2.83yrsno datano data
Evelyn Harrison
Senior VP & Chief Clinical Operations Officer4.83yrsUS$411.67kno data
Kourous Rezaei
Senior VP & Chief Medical Officer4.58yrsno datano data
Guangping Gao
Chief Strategist of Gene Therapy1yrno datano data

3.5yrs

Average Tenure

59yo

Average Age

Experienced Management: ISEE's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Guyer
Executive Chairman13.83yrsUS$1.81m0.060%
$ 340.0k
Glenn Sblendorio
CEO, President & Director3.33yrsUS$2.46m0.25%
$ 1.4m
Axel Bolte
Independent Director13.25yrsUS$79.53k0%
$ 0
Adrienne Graves
Lead Independent Director1.08yrsUS$87.66k0%
$ 0
Mark Blumenkranz
Director0.33yrno datano data
Calvin Roberts
Independent Director1.83yrsUS$110.93k0%
$ 0
David Cheresh
Member of Translational Scientific Advisory Boardno datano datano data
Jane Pritchett Henderson
Independent Director2.83yrsUS$98.91k0%
$ 0
Rakesh Jain
Member of Translational Scientific Advisory Boardno datano datano data

2.8yrs

Average Tenure

65.5yo

Average Age

Experienced Board: ISEE's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 115.3%.


Top Shareholders

Company Information

IVERIC bio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IVERIC bio, Inc.
  • Ticker: ISEE
  • Exchange: NasdaqGS
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$564.276m
  • Shares outstanding: 89.57m
  • Website: https://ivericbio.com

Number of Employees


Location

  • IVERIC bio, Inc.
  • One Penn Plaza
  • 35th Floor
  • New York
  • New York
  • 10119
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ISEENasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 2013
O2TDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2013

Biography

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/28 00:46
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.